Lv1
58 积分 2024-02-20 加入
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database
1天前
已完结
Clinical Pharmacokinetics of Cyclophosphamide
5天前
已完结
Targeting IL-36 in Inflammatory Skin Diseases
12天前
已完结
T cell receptor signaling in the differentiation and plasticity of CD4+ T cells
12天前
已完结
Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases
15天前
已完结
A method for estimating the probability of adverse drug reactions
16天前
已完结
Psoriasis
17天前
已完结
Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update
17天前
已完结
Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes
22天前
已完结
Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease
1个月前
已完结
皖公网安备34019202002308
